13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension. The...
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs....
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
17:37 , Mar 23, 2018 |  BC Week In Review  |  Company News

Amgen examines barriers to PCSK9 inhibitor access

Amgen Inc. (NASDAQ:AMGN) reported data from two retrospective studies suggesting that payer utilization management criteria does not accurately identify high-risk patients who should have access to PCSK9 inhibitors. The first study found that 65% of...
17:22 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Portola reports additional Phase IIIb/IV data of Factor Xa inhibitor antidote AndexXa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported data from 228 patients with Factor Xa inhibitor-associated acute major bleeding in the Phase IIIb/IV ANNEXA-4 trial showing that AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) led to “excellent or good”...
16:42 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

MyoKardia Inc. (NASDAQ:MYOK) reported data from the 10 patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the second cohort of the open-label, U.S. Phase II PIONEER-HCM trial showing that lower doses of oral mavacamten met...
16:34 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events...
16:33 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Berlin Cures' heart failure candidate well tolerated in Phase I

Berlin Cures Holding AG (Zug, Switzerland) reported data from a Phase I trial in 68 healthy volunteers showing that a single IV infusion of heart failure candidate BC007 was well tolerated and eliminated autoantibodies against...